Dana-farber-cancer Institute Inc.

Other

Philip W Kantoff

Gwo-Shu Mary Lee

Christopher Sweeney

Ming Yang

Wanling Xie

Tong Sun

Kazumasa Komura

Myles Edward Brown

Edward Giovannucci

Massimo Loda

Jonathan E Rosenberg

Joaquim Bellmunt

The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

Compositions and methods for screening and diagnosis of prostate cancer

The disclosure provides materials and methods related to using biomarkers for prediction of duration of response to prostate cancer treatment and for treating prostate cancer.

Methods for predicting likelihood of responding to treatment

Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.

Chromosome copy number gain as a biomarker of urothelial carcinoma lethality

There is described a method for prognosis of prostate cancer in a male comprising: (a) determining the length of the CAG trinucleotide repeat of exon 1 of the androgenic receptor gene and/or the length of the TA dinucleotide repeat of the 5 alpha reductase Type II gene or its complement obtained from DNA of the male and (b) correlating the length of the repeat with the aggressiveness and mortality risk of the cancer in the male.

Method for predicting the risk of prostate cancer morbidity and mortality

Growing community of inventors

Brookline, MA, United States of America

Philip W Kantoff